articleDeposito Adademico Digital Universidad De Navarra (University of Navarra)Feb 2, 2024Closed access

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

YTYau, T. (Thomas)PJPark, J.W. (Joong-Won)FRFinn, R.S. (Richard S.)CACheng, A.L. (Ann-Lii)MPMathurin, P. (Philippe)

University of Hong Kong · National Cancer Center · +23 more institutions

Abstract

Background: Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma.
\n
\nMethods: In this randomised, open-label, phase 3 trial done at medical centres across 22 countries and territories in Asia, Australasia, Europe, and North America, patients at least 18 years old with histologically confirmed advanced hepatocellular carcinoma not eligible for, or whose disease had progressed after, surgery or locoregional treatment;…

Citation impact

954
total citations
FWCI
166.03
Percentile
100%
References
33
Citations per year

Authors

27
  • YT
    Yau, T. (Thomas)Corresponding

    University of Hong Kong

  • PJ
    Park, J.W. (Joong-Won)

    National Cancer Center

  • FR
    Finn, R.S. (Richard S.)

    University of California, Los Angeles

  • CA
    Cheng, A.L. (Ann-Lii)

    National Taiwan University Hospital

  • MP
    Mathurin, P. (Philippe)

    Hôpital Claude Huriez

Topics & keywords

Topics
Keywords
  • Sorafenib
  • Nivolumab
  • Hepatocellular carcinoma
  • Medicine
  • Open label
  • Internal medicine
  • Oncology
  • Clinical trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding